APRI (Aprinoia Therapeutics) Total Stockholders Equity: $-100.49 Mil (As of Dec. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aprinoia Therapeutics Total Stockholders Equity?

Aprinoia Therapeutics APRI Total Stockholders Equity is $-100.49 Mil as of Dec. 2023.

Aprinoia Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-100.49 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Aprinoia Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $-3.74. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Aprinoia Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 was -0.19.

Aprinoia Therapeutics  (NAS:APRI) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Aprinoia Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-100.489-0)/26.861
=-3.74

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Aprinoia Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(18.78 + 0.208) / -100.489
=-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Total Stockholders Equity Related Terms

Aprinoia Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Total Stockholders Equity Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Stockholders Equity
-48.69 -75.45 -100.49

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Total Stockholders Equity -48.69 0.00 -75.45 -81.93 -100.49
What does a Total Stockholders Equity of $-100.49 Mil mean?
Aprinoia Therapeutics (APRI) has a Total Stockholders Equity of $-100.49 Mil as of Dec. 2023. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Total Stockholders Equity too high?
Aprinoia Therapeutics' current Total Stockholders Equity is $-100.49 Mil.
How does Aprinoia Therapeutics' Total Stockholders Equity compare to ?
Aprinoia Therapeutics' Total Stockholders Equity of $-100.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Total Stockholders Equity is $-100.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Total Stockholders Equity of $-100.49 Mil. The current Total Stockholders Equity is $-100.49 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Total Stockholders Equity is $-100.49 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.